BioMarin

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. 

CEO
Alexander Hardy
CEOAlexander Hardy
Employees
3,221
Employees3,221
Headquarters
San Rafael, California
HeadquartersSan Rafael, California
Founded
1997
Founded1997
Employees
3,221
Employees3,221

BMRN Key Statistics

Market cap
12.60B
Market cap12.60B
Price-Earnings ratio
174.52
Price-Earnings ratio174.52
Dividend yield
Dividend yield
Average volume
1.90M
Average volume1.90M
High today
$66.60
High today$66.60
Low today
$64.85
Low today$64.85
Open price
$65.40
Open price$65.40
Volume
1.32M
Volume1.32M
52 Week high
$70.98
52 Week high$70.98
52 Week low
$49.26
52 Week low$49.26

Stock Snapshot

As of today, BioMarin(BMRN) shares are valued at $65.08. The company's market cap stands at 12.6B, with a P/E ratio of 174.52.

On 2026-09-17, BioMarin(BMRN) stock moved within a range of $64.85 to $66.60. With shares now at $65.08, the stock is trading +0.4% above its intraday low and -2.3% below the session's peak.

Trading activity shows a volume of 1.32M, compared to an average daily volume of 1.9M.

The stock's 52-week range extends from a low of $49.26 to a high of $70.98.

The stock's 52-week range extends from a low of $49.26 to a high of $70.98.

BMRN News

Simply Wall St 6h
What BioMarin Pharmaceutical Shares' Phase 3 Growth Data Means For Shareholders

BioMarin Pharmaceutical reported Phase 3 CANOPY-HCH-3 trial data for VOXZOGO in children with hypochondroplasia, showing statistically significant gains in grow...

What BioMarin Pharmaceutical Shares' Phase 3 Growth Data Means For Shareholders
TipRanks 2d
BioMarin price target lowered to $97 from $98 at BMO Capital

BMO Capital lowered the firm’s price target on BioMarin (BMRN) to $97 from $98 and keeps an Outperform rating on the shares after the company discontinued devel...

Investing.com 2d
BioMarin to discontinue development of Voxzogo for Noonan syndrome in children - Investing.com

...

BioMarin to discontinue development of Voxzogo for Noonan syndrome in children - Investing.com

Analyst ratings

77%

of 30 ratings
Buy
76.7%
Hold
23.3%
Sell
0%

More BMRN News

Seeking Alpha 2d
BioMarin halts studies for Voxzogo in Noonan syndrome

Shares of BioMarin Pharmaceutical (BMRN) slipped in premarket trading on Tuesday after the company announced plans to discontinue the development of its dwarfis...

BioMarin halts studies for Voxzogo in Noonan syndrome
TipRanks 2d
BioMarin ends VOXZOGO development for Noonan syndrome

BioMarin Pharmaceutical ( (BMRN) ) just unveiled an announcement. On September 15, 2026, BioMarin Pharmaceutical Inc. announced that it had discontinued develo...

TipRanks 3d
BioMarin Pharmaceutical Adds Independent Director to Board

An update from BioMarin Pharmaceutical ( (BMRN) ) is now available. On September 10, 2026, BioMarin Pharmaceutical Inc. expanded its Board of Directors from te...

TipRanks 3d
BioMarin names Robert Plenge, M.D., Ph.D., to board of directors

BioMarin Pharmaceutical (BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company’s Board of Directors, effective September 10....

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.